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Abstract
The control of tuberculosis depends on the identiﬁcation and treatment of infectious patients and their contacts, who are currently identiﬁed
through a combined approach of genotyping and epidemiological investigation. However, epidemiological data are often challenging to obtain,
and genotyping data are difﬁcult to interpret without them. Whole genome sequencing (WGS) technology is increasingly affordable, and
offers the prospect of identifying plausible transmission events between patients without prior recourse to epidemiological data. We discuss
the current approaches to tuberculosis control, and how WGS might advance public health efforts in the future.
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Introduction
The decline in tuberculosis incidence and mortality in western
Europe since the mid-18th century pre-dates the discovery of
the tubercle bacillus in 1882 and the development of drug
treatments in the 1940s. The reasons for this decline are
disputed, but hypotheses range from improvements in living
standards to the isolation of ‘consumptives’ in Poor Law
inﬁrmaries and sanatoria. By 1990, this trend had been
reversed [1].
Historical trends in Africa, Asia and South America are less
well characterized, but historical and phylogeographical data
are consistent with the epidemics on these continents dating
back to the late 19th century, after the disease was probably
(re)-introduced by European colonizers [2,3]. Although this is
relatively late into the colonial period, in India the timing
coincides with a surge in British troop numbers after the 1857
mutiny, and the building of the railways that provided efﬁcient
channels of transmission for disease [4]. The global burden of
disease is now felt most acutely on these continents, where
many of the world’s 2 billion people infected with latent or
active tuberculosis can be found [5].
Today, tuberculosis remains a disease of poverty in high-
income and low/middle-income countries alike. Without major
breakthroughs among experimental vaccines [6], available
control measures include contact tracing, active case-ﬁnding,
prophylaxis, and treatment. In high-income countries, contact
investigations have beneﬁted from advances in genotyping
techniques over the past two decades. The arrival of rapid-
turn-around whole genome sequencing (WGS) technology has
the potential to guide public health teams in all settings with
unprecedented precision.
Epidemiology
Observations that patients with pulmonary tuberculosis often
do not lead to any secondary cases fuelled debate in the 19th
century about whether the disease was communicable at
all [7]. Although this issue was deﬁnitively settled by
Koch’s discovery, how a disease with a predominance of
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non-infectious hosts has managed to infect one in three
individuals on the planet remains poorly understood. Patients
with latent tuberculosis infection have an expected 10%
lifetime risk of reactivation (this rises to 10% per year if the
patients are infected with human immunodeﬁciency virus) [5].
Among patients with active tuberculosis, approximately half
have pulmonary disease; half of these are sputum smear-
positive [8] and are hence considered to be infectious. In a
meta-analysis of pooled data from 41 studies, the risk of
infection among household contacts of these patients with
‘open’ tuberculosis has been quantiﬁed at 50% for the
development of latent tuberculosis infection and <5% for the
development of active disease [9]. Thus, on average, each
patient with open tuberculosis must have the unlikely equiv-
alent of >20 household contacts to result in one further
infectious case (Fig. 1). Reports that hyperinfectious individuals
can be responsible for a large amount of secondary cases in
community outbreaks [10–13] and in experimental settings
[14,15] may offer a potential explanation. Indeed, mathematical
modelling has predicted that if the success of tuberculosis can
be attributed to ‘super-spreaders’, their identiﬁcation and
treatment will be key not only to the control of outbreaks, but
also to combating the disease as a whole [16]. However, the
degree to which super-spreaders account for transmission in
any given community has so far been difﬁcult to quantify.
Public Health Control Measures
Mobile mass X-ray screening was introduced as a tuberculosis
control measure in industrialized countries in the 1930s. By the
1970s, a realization that most patients with active tuberculosis
seek healthcare for their symptoms led to the phasing out of
mass screening and a greater focus on diagnostic services [17].
Although screening remains relevant among patients who are
less likely to seek healthcare [18], targeted contact investiga-
tions to identify ‘source’ and ‘secondary’ cases within outbreaks
are now standard public health practice. Guidance varies across
Europe and the USA, with some countries initiating contact
investigations only for potential ‘source cases’ (patients with
smear-positive pulmonary tuberculosis) and others recom-
mending contact investigations for ‘index cases’ in general,
regardless of whether they are considered to be plausibly
infectious [19,20]. The standardmodel for contact investigations
has been to trace potentially exposed individuals across
widening ‘concentric circles’ until the rate of positive screening
test results reﬂects the background community prevalence of
disease [21]. Most contact investigations focus on household
contacts ﬁrst, and are extended into thewider community only if
at-risk individuals are identiﬁed or if a wider outbreak is
suspected. These environments include schools andworkplaces,
both of which are relatively structured settings in which to
conduct contact investigations, but also pubs/bars or homeless
shelters, where attendees are more transient [18]. Investiga-
tions are dependent on the contacts being named by an index
case and the proportion of ‘close contacts’ that screen positive
for latent or active disease on initial investigation. Because
patients from some of the social groups at highest risk of
tuberculosis may not know the names of their contacts or may
be reluctant to volunteer names, owing to social stigma or
concerns about the legal implications of naming associates, this
approach has its limitations [18,22,23].
FIG. 1. Proportion of household
contacts likely to develop the infectious
form of the disease.
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To better detect routes of transmission, approaches to
contact investigation are evolving beyond the traditional model
of tracing named contacts to social network analyses (SNAs),
which augment this approach by also focusing on places of
contact. By linking patients to one another as well as to places
of social aggregation, SNAs can uncover transmission net-
works better than either ordinary contact investigation
techniques or genotyping [21]. They have the potential to
aid contact investigations even where patients are unwilling to
name their contacts, to link individuals who themselves may
not even have been aware of social connections, and to identify
super-spreaders [11]. Nevertheless, the process of data
collection and analysis is labour-intensive, and SNA has not
yet been widely adopted in routine practice.
Genotyping
Over the past two decades, genotyping has been used to
augment epidemiological investigations by matching isolates
from patients with culture-conﬁrmed tuberculosis. The avail-
able methods have evolved beyond early phage typing to focus
on relatively stable, repetitive elements that can be used to
ﬁngerprint genomes [24]. The ﬁrst such technique to be widely
used was insertion sequence 6110-based restriction fragment
length polymorphism. Although this was a useful adjunct to
contact investigations, restriction fragment length polymor-
phism typing is technically laborious, cannot be used to
distinguish isolates with low IS6110 copy numbers, and
produces results that are difﬁcult to compare across labora-
tories [25]. It has since been superseded by 15-locus and now
24-locus mycobacterial interspersed repetitive-unit–variable-
number tandem-repeat (MIRU-VNTR) typing as the current
standard. MIRU-VNTR typing, which is based on nucleic acid
ampliﬁcation of short repeats at designated loci within the
genome, is less time-consuming, can be performed regardless
of the number of repeats at each locus, and produces a digital
proﬁle that can be readily compared across laboratories [26].
With 24 different MIRU-VNTR loci being explored, the
number of potential combinations is large, as demonstrated in
a Belgian study that found 610 unique proﬁles among 802
consecutively sampled patients over a 3-year period [27].
Although usual practice would be only to investigate potential
epidemiological links between patients whose isolates share
identical MIRU-VNTR proﬁles (i.e. contain the same number of
repeats across all loci), where an outbreak is suspected
contact investigation may be extended to also include patients
with isolates that differ at a single locus. Genotyping can thus
be understood as a means of corroborating or refuting
proposed transmission events between patients with
epidemiological connections, and of linking further cases that
might usefully be included in any contact investigation. As a link
to a transmission network can be ruled out by genotyping with
greater certainty than it can be ruled in [28,29], public health
teams must judge how intensively to search for a possible
epidemiological link between MIRU-VNTR-matched patients in
the knowledge that none might exist. Although scarce
resources need to be used efﬁciently, ending an investigation
prematurely risks further community transmission.
A recent case study of patients from an African immigrant
community resident in different UK cities but linked by MIRU-
VNTR illustrates this problem [30]. Although much effort had
been invested in trying to identify possible links between them,
Fig. 2 illustrates how WGS analysis revealed that only a subset
was related by transmission. The problem is compounded by
data from this and other studies that have shown genotypes
evolving within individuals and outbreaks [30–32]. Although
such events appear to be rare, to accommodate them contact
investigation would need to be routinely widened beyond
exact MIRU-VNTR-matched patients, requiring signiﬁcant
additional resources for a comparatively low return in terms
of positive contacts found.
WGS: Ongoing Challenges and Recent
Developments
The arrival of affordable and rapid WGS technologies repre-
sents a signiﬁcant advance on genotyping techniques, although
the high-throughput platforms producing short reads also pose
new challenges. Algorithms are required to assemble reads
either against a reference genome or on the basis of their
overlapping segments (de novo assembly). Where repetitive
elements in the reference genome exceed the read length that
is particular to the sequencing platform, assembly cannot be
reliably achieved [33]. Whereas raw data are generic,
approaches to the trade-off between maximizing the propor-
tion of the genome covered and optimizing the precision with
which nucleotide variants are called differ [34]. Even though
future sequencing platforms promise longer read lengths that
will allow mapping to repetitive elements within the genome
(including MIRU-VNTR) [35], bioinformatic challenges are
likely to persist. Therefore, if results are to be directly
comparable across laboratories, standardization across plat-
forms and variant calling procedures will be necessary.
The ﬁrst report of WGS being used to investigate an
outbreak of tuberculosis was from Vancouver, where, in
combination with a social network analysis, the technique
helped delineate two separate transmission networks among a
cohort of drug users with identical 24-locus MIRU-VNTR
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proﬁles [11]. The authors applied Bayesian and maximum-
likelihood analyses to infer phylogenetic relationships between
sequenced genomes, to demonstrate the increased resolution
of WGS over MIRU-VNTR typing. Two studies have since
estimated the rate at which single-nucleotide polymorphisms
(SNPs) accumulate within a genome, allowing a time-depen-
dent spectrum of relatedness to be considered directly
[30,36]. Both studies estimated that the 4.4-megabase Myco-
bacterium tuberculosis genome mutates at an average rate of
one SNP every 2 years. Although these results are early
approximations, data such as these allow public health teams
to estimate the time to the most recent common ancestor
(TMRCA) of any two strains, and thereby link patients to an
outbreak before epidemiological data have been gathered. This
constitutes a paradigm shift from the binary interpretation of
MIRU-VNTR typing results (match vs. mismatch) that cur-
rently guide contact investigation.
This potential was tested in the latter study, where the
authors combined this ‘molecular clock’ with data on the
genetic diversity within hosts and between hosts who were
known to be epidemiologically linked. They used the results to
evaluate a series of community-based MIRU-VNTR-restricted
clusters, and demonstrated how patients with known epide-
miological links were more likely to be linked by WGS than
those between whom no epidemiological link had been found
[30]. This unprecedented degree of certainty means that public
health teams will be able to precisely target their contact
investigations, diverting resources away from MIRU-VNTR-
linked cases where the TMRCA precludes recent transmission.
‘Who Gave it to Whom?’ Determining
Directionality from WGS
Although there is evidence of ancestral recombination
between M. tuberculosis and other species [37], on a micro-
evolutionary scale M. tuberculosis can still be regarded as a
largely clonal organism [38,39]. With the exception of
FIG. 2. Whole genome sequencing results for a 24-locus mycobacterial interspersed repetitive-unit–variable-number tandem-repeat (MIRU-
VNTR)-based cluster in the UK. A maximum-likelihood tree of whole genome-sequenced isolates from patients linked by identical 24-locus MIRU-
VNTR proﬁles. Each node represents one or more patient isolates (labelled Pat1 to Pat23), together with the year of isolation. Where more than one
isolate appears in a node, isolates are zero single-nucleotide polymorphisms (SNPs) apart. The genetic distance between adjacent nodes (including
smaller black nodes) is one SNP. Dashed lines represent longer distances, labelled by the number of SNPs (not to scale). The arrow indicates the
root. Nodes are colour-coded to indicate town of residence (the square panel shows geographical distances). Patients are grouped by coloured text
according to known epidemiological links. Where no links are known, the text is white. Other than Pat23, all patients belong to a recent immigrant
community. Walker et al. [30] argue that isolates are likely to be related by recent transmission if separated by ﬁve or fewer SNPs. According to this
metric, the tree not only demonstrates previously unconﬁrmed transmission within and between towns, but also indicates that none of the six
patients in town C are likely to have transmitted to each other. The image has been adapted form Walker et. al. [30] (Lancet Infectious Diseases).
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convergent evolution (or ‘homoplasy’), which is largely con-
ﬁned to genomic regions under signiﬁcant selection pressure
from antimicrobial agents [40], the relative paucity of back-
ward mutation suggests that the pattern of accumulating SNPs
can be used as a marker of micro-evolution within any one
lineage of tuberculosis [41]. This ‘evolution by descent’ offers
the potential for contact investigations to use WGS data as an
indicator of direction of transmission within an outbreak, as
illustrated in Fig. 3.
The ﬁrst proof of this principle was presented by Sch€urch
et al., who demonstrated a stepwise accumulation of SNPs
between patients in a well-characterized transmission chain
[41]. Walker et al. have since demonstrated how the topology
of a phylogenetic tree might signal the existence of a common
source of secondary cases (a ‘super-spreader’), whether or not
that source case has been diagnosed. They describe an
example of an outbreak in which the secondary cases coalesce
in a common root on the phylogenetic tree, accurately
predicting the existence of a common source case that was
sequenced at a later date [30]. Fig. 3 illustrates the principle.
An accurate reconstruction of a transmission network
requires not only a complete set of closely related but non-
identical sequences, but also the identiﬁcation of cases of open
pulmonary tuberculosis. Where sufﬁcient clinical and epide-
miological data are available for a source case to be
distinguished from secondary cases, contact investigation can
be targeted accordingly. However, inferences about direction-
ality also offer epidemiologists the prospect of identifying
super-spreaders and of estimating their relative impact on the
overall incidence of tuberculosis—information that could
inform planning of and resource allocation to future contact
investigations.
Questions and Challenges for the Future
Current centralized tuberculosis surveillance databases link
patients by genotype [8,42]. Although these systems can help
to identify trans-regional outbreaks, they can also trigger costly
investigations where no outbreaks have occurred. The extent
to which routine WGS will be able to reduce the inherent
inefﬁciencies in this system, accurately linking patients across
regional boundaries, requires further investigation. On the
basis of the limited data currently available from low-incidence
areas, routine WGS could enable public health teams to target
their investigations at cases linked by a short TMRCA,
between whom they can expect epidemiological linkage to
exist. How this might work in a high-transmission setting is less
clear. If three or four generations of transmission are possible
over a short period of time, as few as three or four SNPs might
separate the index and ﬁnal case in a transmission chain. This
could mislead public health teams to search for an epidemi-
ological link where none might exist. It is therefore possible
that the thresholds for investigation will need to be calibrated
for each setting in which this technology is applied.
The ability to read the topology of a phylogenetic tree for
evidence of a super-spreader as an outbreak evolves may be
less dependent on the setting. How effectively this can be
done, and how relevant the identiﬁcation of super-spreaders is
to the design of new disease control strategies, remains to be





FIG. 3. Inferring direction of transmission from genetic relationships.
A demonstration is given of how direction of transmission may be
inferred from whole genome sequencing data. Data are invented and,
to illustrate the principle, are stipulated to be complete. Four
hypothetical sequences (each represented by four nucleotides) signal
different patterns of transmission between four hypothetical cases.
Arrows represent the ‘root’ to the tree, indicating the next nearest
other sequence. Black lines indicate one single-nucleotide polymor-
phism difference. (a) Four genomes are identical, and no direction can
be inferred. (b) A mutation has occurred between the ﬁrst two and the
latter two. The root suggests that transmission was from left (AAAA)
to right (AAAC), but the source case cannot be inferred. (c)
Transmission chain from left to right, each patient accumulating a
new mutation and passing the infection on to the next. (d) A central
source case infects three secondary cases, each with a separate
mutation not seen in other cases. (e) Four cases, each with a separate
mutation not seen in other cases. For any one of these cases to have
infected the other cases, two independent mutations would have had
to occur at the same locus in separate individuals. The more likely
explanation is an undiagnosed common source case.
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SNA is also key [11]. However, the prospect of preferentially
focusing contact investigation on a super-spreader’s contacts,
or of triggering ‘targeted’ active case-ﬁnding when an undiag-
nosed super-spreader is suspected, will be attractive wherever
public health resources are limited.
However, even if this technology can fulﬁl its promise, there
are numerous obstacles to low-income, high-incidence coun-
tries deriving beneﬁt from it. Not only is substantial capital
investment required to procure the technology, but the costs
of maintaining healthcare workers to enact interventions can
also be prohibitive. As next-generation sequencing platforms
currently require mycobacterial culture and DNA extraction,
the limited laboratory facilities in many endemic countries
pose a further obstacle [43].
Nevertheless, a precedent for deploying advanced technol-
ogy where it is most required has been set by the WHO and
USAID/Gates Foundation initiative to roll out the Xpert MTB/
RIF assay [44]. As new technologies are introduced, some
capable of producing a whole genome sequence from as little
DNA as is contained in a primary sample, it is possible that
culture steps could be bypassed [35,45]. Early signs that in silico
drug sensitivity testing will be possible make this a still more
appealing prospect [46]. If a clear beneﬁt to public health and
tuberculosis control is therefore demonstrated by future
research, the drive to overcome the remaining obstacles to
the implementation of this technology where it could have the
greatest impact will grow.
Conclusions
The global political challenge of addressing poverty and other
underlying causes of the tuberculosis pandemic are immense.
However, tuberculosis control is also a local issue that
requires public health policy and public health teams to
interrupt the spread of this disease wherever it can be
identiﬁed. WGS technology has the potential to relate patient
isolates to one another with unprecedented precision. The
data produced represent a qualitative and quantitative
improvement on current genotyping methods, and will enable
public health teams to target their contact investigations with
greater conﬁdence. The impact of WGS technology on the
landscape of microbiology has been widely predicted [33], but
its impact on tuberculosis control may be equally signiﬁcant.
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